Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcitriol→

Calcitriol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
32222-06-3
Molecular formula
C27H44O3
Molecular weight
416.6 g/mol
Drug class
Active vitamin D3 hormone (1,25-dihydroxyvitamin D3)vitamin D receptor agonist
Mechanism of action
Binds the nuclear vitamin D receptor, regulating gene transcription involved in intestinal calcium and phosphate absorption, renal mineral handling, parathyroid hormone regulation and bone metabolism.
Indications / reported uses
  • Treatment of hypocalcaemia and secondary hyperparathyroidism associated with chronic kidney disease in selected patients
  • Treatment of hypoparathyroidism and selected vitamin D-dependent rickets or related disorders; route and indication depend on the specific oral or intravenous formulation

Sources: US DailyMed — Rocaltrol (calcitriol) · NLM MeSH — Calcitriol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcitriol Environmental Risk Assessment (ERA) (the Calcitriol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.